Despite of the controversial effect of autotaxin and its product signaling, it is clear fact that the level of autotaxin is elevated in MS patients and the inhibition of S1P, another product of the enzyme, shows significant therapeutic effect on MS. This evidence concerns the gene ENPP2 and myeloid sarcoma.